Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study-Reference-Cited by-同舟云学术

Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study

Published:2015-10-28 Issue:1 Volume:43 Page:134-144
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Ahn J.¹,Lee H. M.²,Lim J. K.³,Pan C. Q.⁴,Nguyen M. H.⁵,Ray Kim W.⁵,Mannalithara A.⁵,Trinh H.⁶,Chu D.⁷,Tran T.⁸,Min A.⁹,Do S.¹⁰,Te H.¹¹,Reddy K. R.¹²,Lok A. S.¹³

Affiliation:

1. Division of Gastroenterology & Hepatology; Oregon Health & Science University; Portland OR USA

2. Gastroenterology/Hepatology Division; Tufts Medical Center; Boston MA USA

3. Digestive Diseases; Yale University; New Haven CT USA

4. Department of Medicine; NYU Langone; New York NY USA

5. Division of Gastroenterology & Hepatology; Stanford University; Stanford CA USA

6. San Jose Gastroenterology; San Jose CA USA

7. Albert Einstein College of Medicine; New York NY USA

8. Department of Medicine; Cedars Sinai Medical Center; Los Angeles CA USA

9. Division of Gastroenterology; Mount Sinai Beth Israel; New York NY USA

10. Digestive Health Associates of Texas; Plano TX USA

11. Digestive Disease Center; University of Chicago; Chicago IL USA

12. Division of Gastroenterology and Hepatology; University of Pennsylvania; Philadelphia PA USA

13. Division of Gastroenterology and Hepatology; University of Michigan; Ann Arbor MI USA

Funder

Bristol Myers Squibb

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13440/fullpdf

Reference28 articles.

1. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B;Chang;N Engl J Med,2006

2. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B;Lai;N Engl J Med,2006

3. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B;Chang;Hepatology,2010

4. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy;Shouval;J Hepatol,2009

5. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901;Manns;Expert Opin Drug Saf,2012

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect, or residual confounding?;Hepatology;2023-10-20

2. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study;Gastroenterology;2023-10

3. Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection;Alimentary Pharmacology & Therapeutics;2023-09-13

4. Past, present, and future of long-term treatment for hepatitis B virus;World Journal of Gastroenterology;2023-07-07

5. Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes;Journal of Hepatocellular Carcinoma;2023-03